journal
https://read.qxmd.com/read/36961938/drug-treatment-strategies-for-paget-s-disease-relieving-pain-and-preventing-progression
#1
JOURNAL ARTICLE
Daniela Merlotti, Domenico Rendina, Guido Cavati, Veronica Abate, Alberto Falchetti, Christian Mingiano, Ranuccio Nuti, Luigi Gennari
INTRODUCTION: Paget's disease of bone (PDB) is a focal bone disorder caused by a marked dysregulation of osteoblasts and osteoclasts in basic multicellular units, leading to abnormal and disorganized deposition of collagen fibers (the so-called 'woven bone'). Therefore, pagetic bones are increased in size, and at increased risk for bone pain, deformities, fractures, osteoarthritis, and, more rarely, neoplastic degeneration. AREAS COVERED: In this review, we revise the available information concerning the pharmacological treatment of PDB...
March 28, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36963373/current-factor-ix-replacement-options-for-hemophilia-b-and-the-challenges-ahead
#2
JOURNAL ARTICLE
Massimo Franchini, Marco Zaffanello, Daniele Focosi
INTRODUCTION: Therapy for hemophilia B is aimed at replacing the congenital deficiency of coagulation factor IX (FIX). For replacement therapy, several FIX concentrates derived from donated human plasma or engineered by recombinant DNA technology are currently commercially available. The use of these products is well established and permit patients a relatively normal life. To further improve treatment efficacy, recombinant FIX products with a prolonged half-life have been developed, allowing relaxed prophylactic dosing and reducing treatment burden...
March 24, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36961877/optimizing-the-management-of-patients-with-worsening-heart-failure-beyond-heart-failure-hospitalization
#3
JOURNAL ARTICLE
Alberto Esteban Fernández, Alejandro Recio Mayoral, Alvaro González Franco, Julio Núñez Villota, Sonia Mirabet, Jorge Rubio Gracia, José González Costello, Juan Luis Bonilla Palomas, Carlos Escobar Cervantes
INTRODUCTION: Worsening heart failure (HF) is associated with a high risk of death and HF hospitalization. AREAS COVERED: A systematic search was conducted on PubMed (MEDLINE), using the MeSH terms [Heart failure] + [Worsening] + [Treatment] + [Vulnerable period] up to February 2023. Original data from clinical trials, and observational studies were critically analyzed. EXPERT OPINION: Although the vulnerable period has been traditionally limited to the first 6 months after HF hospitalization, the fact is that there are other clinical scenarios in which the patient is particularly vulnerable...
March 24, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36958727/a-2023-update-on-the-advancements-in-the-treatment-of-agitation-in-alzheimer-s-disease
#4
JOURNAL ARTICLE
Daniel Lee, Emily D Clark, Inga M Antonsdottir, Anton P Porsteinsson
INTRODUCTION: Neuropsychiatric symptoms (NPS) in Alzheimer's Disease (AD) are associated with negative outcomes for patients and their care partners. Agitation is one of the most common and distressing NPS, yet we lack safe and effective treatment options. While nonpharmacologic interventions are considered first line treatment, these may not be effective or appropriate for every patient. Our current approaches to the pharmacologic treatment of agitation in AD consist of the off-label use of antipsychotics, sedative/hypnotics, anxiolytics, mood-stabilizing anticonvulsants, acetylcholinesterase inhibitors, NMDA receptor antagonists, and antidepressants...
March 23, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36951262/new-developments-in-the-management-of-vulvovaginal-atrophy-a-comprehensive-overview
#5
JOURNAL ARTICLE
Gilbert G G Donders, Francesca H W V Donders
INTRODUCTION: Proper recognition and individualized therapy of vulvovaginal atrophy (VVA) is paramount. AREAS COVERED: Assessment of VVA should be done using several questionnaires in combination with wet mount microscopy to determine Vaginal Cell Maturation Index (VCMI) and infections. PubMed searches were done between 1march 2022 and 15 Oct 2022.Low dose vaginal estriol seems safe, efficient, and could be used in patients with contraindications for steroid hormones such as women with a history of breast cancer, and should therefore be considered as first choice hormonal treatment, when non-hormonal treatments fail...
March 23, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36946625/an-update-on-the-use-of-sphingosine-1-phosphate-receptor-modulators-for-the-treatment-of-relapsing-multiple-sclerosis
#6
JOURNAL ARTICLE
Laura Dumitrescu, Athanasios Papathanasiou, Catalina Coclitu, Afagh Garjani, Nikos Evangelou, Cris S Constantinescu, Bogdan Ovidiu Popescu, Radu Tanasescu
INTRODUCTION: Multiple sclerosis (MS) is an immune-mediated disorder of the CNS manifested by recurrent attacks of neurological symptoms (related to focal inflammation) and gradual disability accrual (related to progressive neurodegeneration and neuroinflammation). Sphingosine-1-phosphate-receptor (S1PR) modulators are a class of oral disease-modifying therapies (DMTs) for relapsing MS. The first S1PR modulator developed and approved for MS was fingolimod, followed by siponimod, ozanimod, and ponesimod...
March 22, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36946287/conventional-biological-disease-modifying-anti-rheumatic-drugs-and-janus-kinase-inhibitors-and-varicella-zoster-virus
#7
JOURNAL ARTICLE
Fabiola Atzeni, Francesco Gozza, Agostino Riva, Alessandra Alciati, James Galloway
INTRODUCTION: The advent of biological disease-modifying anti-rheumatic drugs (bDMARDs), and more recently of Janus kinase inhibitors (JAKi), has had a major impact on the herpes zoster (HZ) reactivation, which represents an important clinical challenge in the treatment of inflammatory arthritis (IA) in patients with a complete pharmacological control of peripheral inflammation. AREAS COVERED: In this review, we provide an overview on the effects of conventional DMARDs/ bDMARDs and JAKi on HZ reactivation...
March 28, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36946229/an-update-on-potential-pharmacotherapies-for-cognitive-impairment-in-bipolar-disorder
#8
JOURNAL ARTICLE
Danica E Johnson, Roger S McIntyre, Rodrigo B Mansur, Joshua D Rosenblat
INTRODUCTION: Cognitive impairment is a core feature of bipolar disorder (BD) that impedes recovery by preventing the return to optimal socio-occupational functioning and reducing quality of life. Presently, there are no efficacious treatments for cognitive impairment in BD, but many pharmacological interventions are being considered as they have the potential to target the underlying pathophysiology of the disorder. AREAS COVERED: This review summarizes the available evidence for pharmacological interventions for cognitive impairment in bipolar disorder...
March 22, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36946205/current-and-emerging-pharmacotherapy-for-menstrual-migraine-a-narrative-review
#9
JOURNAL ARTICLE
Claire E J Ceriani, Stephen D Silberstein
INTRODUCTION: In this article, we discuss menstrual migraine (MM), which can be categorized as menstrually related migraine (MRM) or pure menstrual migraine (PMM). MM attacks are often longer, more severe, and harder to treat than other migraine attacks. Appropriate treatment strategies include acute treatment, short term preventive treatment, and daily preventive treatment, depending on the patient's pattern of migraine and occurrence of migraine outside the menstrual period. AREAS COVERED: A PubMed, Cochrane Library, Medline, and Ovid search from inception to October 2022 provided articles relating to MM pathophysiology and treatment...
March 22, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36943916/acalabrutinib-in-chronic-lymphocytic-leukemia
#10
EDITORIAL
Enrica Antonia Martino, Antonella Bruzzese, Ernesto Vigna, Enrico Iaccino, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Gianfranco Filippelli, Antonino Neri, Fortunato Morabito, Massimo Gentile
No abstract text is available yet for this article.
March 21, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36927284/montelukast-as-a-potential-treatment-for-covid-19
#11
JOURNAL ARTICLE
Matthew W McCarthy
INTRODUCTION: Montelukast is a leukotriene inhibitor that is widely used to treat chronic asthma and allergic rhinitis. The drug interferes with molecular signaling pathways produced by leukotrienes in a variety of cells and tissues throughout the human body that lead to tightening of airway muscles, production of aberrant pulmonary fluid (airway edema), and in some cases, pulmonary inflammation. AREAS COVERED: Montelukast has also been noted to have anti-inflammatory properties, suggesting it may have a role in the treatment of coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has been noted to induce misfiring of the immune system in some patients...
March 19, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36932818/vv116-as-a-potential-treatment-for-covid-19
#12
JOURNAL ARTICLE
Matthew W McCarthy
INTRODUCTION: VV116 is a chemically-modified version of the antiviral remdesivir with oral bioavailability and potent activity against SARS-CoV-2. AREAS COVERED: The optimal treatment of standard-risk outpatients who develop mild-to-moderate COVID-19 is controversial. While several therapeutic are currently recommended, including nirmatrelvir-ritonavir (Paxlovid), molnupiravir, and remdesivir, these treatments have substantial drawbacks, including drug-drug interactions and questionable efficacy in vaccinated adults...
March 18, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36927378/glp-1-gip-analogs-potential-impact-in-the-landscape-of-obesity-pharmacotherapy
#13
JOURNAL ARTICLE
Ryan A Lafferty, Peter R Flatt, Nigel Irwin
INTRODUCTION: Obesity is recognized as a major healthcare challenge. Following years of slow progress in discovery of safe, effective therapies for weight management, recent approval of the glucagon-like peptide 1 receptor (GLP-1R) mimetics, liraglutide and semaglutide, for obesity has generated considerable excitement. It is anticipated these agents will pave the way for application of tirzepatide, a highly effective glucose-dependent insulinotropic polypeptide receptor (GIPR), GLP-1R co-agonist, recently approved for management of type 2 diabetes mellitus...
March 28, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36927370/intravenous-immunoglobulin-gamunex%C3%A2-10-is-licensed-for-the-treatment-of-severe-acute-exacerbations-of-myasthenia-gravis
#14
JOURNAL ARTICLE
Francesc Camps, Howard W Sander, Sandra Fernández
No abstract text is available yet for this article.
March 16, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36927238/an-evaluation-of-pharmacological-options-for-cushing-s-disease-what-are-the-state-of-the-art-options
#15
JOURNAL ARTICLE
Marianna Martino, Nairus Aboud, Beatrice Lucchetti, Gianmaria Salvio, Giorgio Arnaldi
INTRODUCTION: : Cushing's syndrome (CS) is associated with significant morbidity and mortality if it is not treated. Cortisol normalisation is a key goal to treatment. Pituitary surgery remains the first-line approach for Cushing's disease (CD), but sometimes it is impracticable, unsuccessful or complicated by recurrence. Medical therapy has been historically considered a palliative treatment. However, in the latest years interest on this topic has grown due to both the availability of new drugs and the re-evaluation of the old, commonly used drugs in clinical practice...
March 16, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36922391/pharmacotherapeutic-advances-for-splenomegaly-in-myelofibrosis
#16
JOURNAL ARTICLE
Douglas Tremblay, John Mascarenhas
INTRODUCTION: Myelofibrosis is a hematologic malignancy with a variety of clinical manifestations including splenomegaly, which is present in approximately 80% of newly diagnosed patients. JAK inhibitors are the mainstay of pharmacologic treatment for splenomegaly in myelofibrosis, although spleen size reduction is not universal, and the duration of benefit is only moderately durable. AREAS COVERED: We first discuss the pathobiology of splenomegaly in myelofibrosis before detailing approved and novel pharmacotherapies that can reduce spleen size while also highlighting non-pharmacologic approaches...
March 15, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36919576/long-acting-antipsychotics-in-the-treatment-of-schizophrenia-opportunities-and-challenges
#17
JOURNAL ARTICLE
Peter M Haddad, Christoph U Correll
INTRODUCTION: Maintenance antipsychotic treatment improves multiple outcomes in people with schizophrenia. These benefits are challenged by medication nonadherence, which is a common occurrence. Long-acting injectable antipsychotic (LAI) formulations were developed to reduce nonadherence and thereby improve outcomes. This narrative review is based on a PubMed search (January 2000 - August 2022) for studies on LAI antipsychotics. AREAS COVERED: Opportunities and challenges associated with LAIs are reviewed...
March 15, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36820516/profile-of-tirzepatide-in-the-management-of-type-2-diabetes-mellitus-design-development-and-place-in-therapy
#18
JOURNAL ARTICLE
Lina Naseralallah, Bodoor Aboujabal
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is one of the leading causes of morbidity and mortality. Peptide-based multi-targeting agonists represent a new paradigm in metabolic pharmacology as they manifest multiplexed pharmacological actions over mono-agonists. Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) agonist that has been recently approved by the FDA. This review aims to summarize the available evidence on the discovery, pharmacology, pharmacokinetic, pharmacodynamic, efficacy, and safety of tirzepatide in the pharmacotherapy of T2DM...
February 23, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36799287/the-correlations-between-steady-state-concentration-duration-of-action-and-molecular-weight-of-glp-1ras-and-their-efficacy-and-gastrointestinal-side-effects-in-patients-with-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis
#19
JOURNAL ARTICLE
Ruoyang Jiao, Chu Lin, Shuzhen Bai, Xiaoling Cai, Suiyuan Hu, Fang Lv, Wenjia Yang, Xingyun Zhu, Linong Ji
BACKGROUND: To assess the influence of steady-state concentration, duration of action and molecular weight of glucagon-like peptide-1 receptor (GLP-1RA) on efficacy and gastrointestinal (GI) side effects in patients with type 2 diabetes mellitus (T2DM). METHODS: PubMed, EMBASE, the Cochrane Center Register of Controlled Trials for Studies and Clinicaltrial.gov were searched from inception to April 2022. Randomized controlled trials (RCTs) comparing GLP-1RA versus non-GLP-1RA agents in patients with T2DM were included...
February 22, 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36794331/risk-management-of-medication-errors-a-novel-conceptual-framework
#20
JOURNAL ARTICLE
Richard Despott, Janet Sultana, Liberato Camilleri, Janis Vella Szij, Anthony Serracino Inglott
BACKGROUND: Medication error is a common cause of patient harm. The study aims to propose a way to manage the risk of medication errors in a novel way, by identifying practice areas where mitigating patient harm should be prioritized using a risk management approach. METHODS: Suspected Adverse Drug Reactions (sADRs) in Eudravigilance database over three years were reviewed to identify preventable medication errors. These were classified using a new method based upon the root cause underlying pharmacotherapeutic failure...
February 15, 2023: Expert Opinion on Pharmacotherapy
journal
journal
34813
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.